Agilent Technologies has released SureSelect Human All Exon v2, an updated version of the target enrichment kit it developed in collaboration with the Broad Institute (see news brief, this issue). The new version targets 38 megabases of the human genome and adds content recently determined to be in the expressed genome. The company has also rebalanced the mixture of probes to maximize capture efficiency and uniformity across the exome. Specifically, the kit covers 99.01 percent of human exons defined by the NCBI Consensus CDS Database from September 2009; 93.29 percent of RefSeq genes; 95.07 percent of RefSeq transcripts from June 2010; and 90 percent of miRNA in miRBase v14.
The new kit is different from Agilent's other exome kit, the SureSelect Human All Exon 50 Mb kit, which it developed with the Wellcome Trust Sanger Institute.